Previous 10 | Next 10 |
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase ...
Lumos Pharma (NASDAQ: LUMO) , a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (“PGHD”) through phase 2 clinical trials, has received a notice of allowance for a submitted patent. The notice was received from the U.S. P...
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company recei...
2024-03-07 17:45:08 ET Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Conference March 07, 2024 04:30 PM ET Company Participants Lisa Miller - Vice President, IR Rick Hawkins - CEO and Chairman John McKew - President and CSO Duke Pitukcheewanont - CMO Lori La...
2024-03-07 16:32:56 ET More on Lumos Pharma Lumos Pharma, Inc. 2023 Q3 - Results - Earnings Call Presentation Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for...
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Pisit “Duke” ...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
2024-03-06 17:35:33 ET Major earnings expected after the bell on Thursday include: Costco Wholesale Corporation ( COST ) Broadcom ( AVGO ) DocuSign ( DOCU ) Marvell Technology ( MRVL ) Petróleo Brasileiro ( PBR ) Read the full article o...
2024-03-06 17:20:06 ET More on Lumos Pharma Lumos Pharma, Inc. 2023 Q3 - Results - Earnings Call Presentation Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for...
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results ...
News, Short Squeeze, Breakout and More Instantly...
Lumos Pharma Inc. Company Name:
LUMO Stock Symbol:
NASDAQ Market:
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months ...
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will hos...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...